Store at 28C, away from light and moisture
Professor Muresanus research contributions include: Principal investigator for the CARS trial (Cerebrolysin and Recovery After Stroke), the largest randomized controlled trial examining functional outcomes Lead investigator for CAPTAIN trials evaluating Cerebrolysin in traumatic brain injury populations Extensive research on neurotrophic factor signaling and neuroprotective mechanisms Development of multimodal therapeutic strategies combining Cerebrolysin with rehabilitation Investigations of dose-response relationships and optimal treatment protocols across neurological conditions His work has been instrumental in advancing understanding of peptidergic neuroprotection, though clinical translation challenges remain a focus of ongoing investigation
Important considerations: BPC-157 is sold for research purposes only and is not intended for human consumption No human clinical trials have established safety or efficacy Quality and purity of research peptides vary significantly between suppliers Individual responses may differ significantly from research findings Always consult with a qualified healthcare provider before considering any peptide research This content does not constitute medical advice, diagnosis, or treatment recommendations The decision to use any research compound is a personal one that should be made with full awareness of the legal status, limited human data, and potential risks involved
AOP, advanced oxidation process
The peptide is functionally degraded beyond useful application for most protocols
IM injections also allow for larger volumestypically up to 3-5mL depending on the muscle, compared to 1-2mL maximum for SubQ
